Menu
Back to Archived Journals » Core Evidence » Volume 2 » Issue 3
Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
Authors Cassinotti A, Ardizzone S, Bianchi-Porro G
Published 15 September 2007 Volume 2007:2(3)
Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro
Department of Clinical Science, Chair of Gastroenterology, “L. Sacco” University Hospital, Milan, Italy
Introduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing/remitting course with transmural inflammation of potentially any section of the digestive tract. Certolizumab pegol (CZP) is a pegylated Fc-free Fab’ fragment of a humanized anti-TNF-alfa monoclonal antibody that is in development for clinical use in CD.
Aims: To review the available data with CZP in CD, to investigate its possible place in therapy.
Evidence review: Available studies suggest that CZP has the potential to achieve and maintain clinical response and remission in moderate to severe CD, and to improve quality of life compared with placebo. Further studies with CZP are also ongoing.
Place in therapy: Although only suggested by currently available studies, successive clinical practice and further ongoing trials may confirm a positive role for CZP as a new anti-TNF treatment in CD. The impact on clinical management or on resources cannot be estimated until the results from all phase III clinical trials are available and the price is determined.
Key words: anti-TNF, biological therapy, certolizumab pegol, Crohn’s disease
© 2007 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.